Form 4: Processa Pharmaceuticals Director Acquires Shares in Open Market Transaction

Justin W. Yorke, a director at Processa Pharmaceuticals, purchased 12,400 shares of common stock at a price of $0.7975 per share.

Summary

• Justin W. Yorke, a director of Processa Pharmaceuticals, acquired 12,400 shares of common stock on January 27, 2025.
• The shares were purchased at a price of $0.7975 each.
• The transaction was made through a Directed Trust Company FBO Justin Yorke IRA.
• Following the transaction, Mr. Yorke also beneficially owns 31,232 shares through Richland Fund, LLC and 3,737 shares directly.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment, as it simply reports a transaction. The purchase by a director could be seen as a slightly positive signal, but it's not a major event.

Positives

• The purchase of shares by a director can be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade in their company's stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the United States, ensuring transparency of insider trading.
• The transaction is typical for directors who may acquire shares through various means, including open market purchases.

Stakeholder Impact

• The share purchase may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Processa Pharmaceuticals, insider trading, share purchase, director, common stock, equity